AI Article Synopsis
- Rituximab, a medication often used in certain diseases, can lead to late-onset neutropenia (R-LON), a side effect that usually resolves without serious issues.
- A case study discusses a 91-year-old woman with kidney problems who developed febrile neutropenia 54 days after her last rituximab treatment for a specific type of vasculitis.
- The patient’s condition improved with treatment using granulocyte colony-stimulating factor and antibiotics, highlighting the potential dangers of R-LON in older adults or those with pre-existing health conditions.
Article Abstract
An underestimated side effect of rituximab is late-onset neutropenia (R-LON), which often resolves spontaneously and rarely results in a severe infection. We herein report a case of febrile neutropenia due to R-LON in a 91-year-old woman with renal failure who was treated with rituximab to induce remission of MPO-ANCA-associated vasculitis. Fifty-four days after the last rituximab administration, the patient was hospitalized for febrile neutropenia due to R-LON, which improved with granulocyte colony-stimulating factor and antibiotics. Although R-LON may resolve spontaneously and remain unnoticed, it can cause severe infections in the elderly and patients with renal failure.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2169/internalmedicine.3357-23 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Late-onset Neutropenia after Rituximab Treatment for MPO-ANCA-associated Vasculitis.
Intern Med
July 2024
Department of Nephrology, Kurashiki Central Hospital, Japan.
Article Synopsis
- Rituximab, a medication often used in certain diseases, can lead to late-onset neutropenia (R-LON), a side effect that usually resolves without serious issues.
- A case study discusses a 91-year-old woman with kidney problems who developed febrile neutropenia 54 days after her last rituximab treatment for a specific type of vasculitis.
- The patient’s condition improved with treatment using granulocyte colony-stimulating factor and antibiotics, highlighting the potential dangers of R-LON in older adults or those with pre-existing health conditions.
Late-Onset Neutropenia after Rituximab Treatment for Adult-Onset Nephrotic Syndrome.
Case Rep Nephrol
March 2019
Department of Nephrology, Tokyo Women's Medical University, Tokyo, Japan.
A 41-year-old woman developed nephrotic syndrome at the age of 32 and was diagnosed with minimal change nephrotic syndrome based on a renal biopsy. Although remission was achieved with administration of prednisolone (PSL) and cyclosporine, the nephrotic syndrome recurred. She was also started on rituximab (RTX).
View Article and Find Full Text PDFObjectives: Late-onset neutropenia after rituximab (RTX) therapy (R-LON) has been widely reported, but clinical studies on a large number of cases are limited. In this study, we aimed to investigate the incidence and risk factors of R-LON.
Patients And Methods: In this study, we retrospectively analyzed data of 213 enrolled B-cell lymphoma patients (male 114; female 99) treated with RTX at a single institution.
Disseminated cryptococcosis in a non-Hodgkin's lymphoma patient with late-onset neutropenia following rituximab-CHOP chemotherapy: a case report and literature review.
Mycopathologia
September 2011
Department of Infectious Disease, Tokyo Women's Medical University, Tokyo, Japan.
Rituximab-related late-onset neutropenia (R-LON) is an adverse event associated with rituximab. A 65-year-old woman presented with diffuse large B-cell lymphoma of the kidney without bone marrow involvement. She was treated with 4 cycles of CHOP chemotherapy consisting of doxorubicin, cyclophosphamide, vincristine, and prednisolone at 4-week intervals.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!